Cardio-oncology is a medical specialty focused on protecting the heart before, during, and after cancer treatment. It exists because many effective cancer therapies can damage the cardiovascular system, sometimes during treatment and sometimes years or even decades later. A cardio-oncology team works alongside oncologists to monitor heart function, catch problems early, and keep patients safely on the cancer treatments they need.
Why Cancer Treatment Can Harm the Heart
Heart cells don’t divide after birth the way other cells do, which makes them uniquely vulnerable. Many cancer drugs work by disrupting cell growth and signaling pathways, and heart cells become what researchers call “innocent bystanders” of that process. The damage shows up in different ways depending on the type of treatment.
Certain chemotherapy drugs cause direct, cumulative injury to heart muscle cells. Each dose adds to the total burden, and the damage can be irreversible. Other targeted therapies work differently. Some block a protein that heart cells rely on for normal maintenance and stress response. Without that protein’s protective signaling, the heart muscle becomes weaker and more susceptible to further injury, particularly if the patient has also received chemotherapy.
Newer immunotherapy drugs carry their own risks. These treatments work by releasing the brakes on the immune system so it can attack cancer, but sometimes the immune system also attacks heart tissue. The resulting inflammation of the heart muscle occurs in roughly 0.3% to 1.1% of patients on these drugs, and that number is likely an undercount because some cases produce no obvious symptoms. When it does occur, it’s serious: fatal outcomes have been reported in 38% to 46% of affected patients even with aggressive treatment.
Radiation therapy directed at the chest poses a different timeline of risk. Acute heart inflammation can appear within hours of treatment, but the more common pattern is a slow, silent process. Radiation-induced heart disease typically takes 5 to 10 years to surface, and some effects don’t appear for decades. Long-term studies of Hodgkin lymphoma survivors found that about 31% developed valve problems within 10 years of chest radiation, and that proportion exceeded 90% after 22 years. Because the damage accumulates so quietly, it’s often significantly underdiagnosed.
Who Needs Cardio-Oncology Care
A cardio-oncology service covers the entire journey of a person with cancer, starting at diagnosis. Patients are typically referred before treatment begins so their baseline heart function can be assessed and their individual risk level established. People with pre-existing heart conditions, older adults, and those receiving known high-risk therapies are the most obvious candidates, but the field also serves patients who develop unexpected cardiac symptoms during treatment.
Perhaps the most overlooked group is long-term cancer survivors. Childhood cancer survivors face dramatically elevated cardiovascular risk: one modeling study estimated that a survivor’s probability of developing heart failure by age 50 was 13.7%, with a relative risk 33 times higher than a sibling who never had cancer. Adult survivors of breast cancer, lymphoma, and other cancers treated with chest radiation or cardiotoxic drugs also need structured, ongoing cardiac monitoring for years after their last treatment.
How Heart Damage Is Detected Early
For decades, doctors relied on a single measurement to track heart health during cancer treatment: the ejection fraction, which estimates how much blood the heart pumps out with each beat. The problem is that ejection fraction drops only after significant damage has already occurred. It’s not sensitive enough to catch the early, subtle changes that signal trouble ahead.
A newer imaging technique called global longitudinal strain has changed that. It uses specialized ultrasound tracking to measure how well the heart muscle fibers shorten during each contraction. A relative drop of more than 15% during cancer treatment is the recommended threshold for suspecting hidden cardiac dysfunction, often well before the ejection fraction shows any decline. European cardiology guidelines now include strain measurement as a key element in diagnosing treatment-related heart damage. This earlier detection window matters because catching problems at this stage allows doctors to start protective medications and, critically, avoid unnecessary interruptions to cancer therapy.
Blood tests add another layer of surveillance. Troponin, a protein released when heart cells are injured, and natriuretic peptides, which rise when the heart is under stress, are both measured at regular intervals. Patients who develop treatment-related heart muscle weakness show significantly higher levels of both markers compared to those without cardiac complications. Prolonged troponin elevation during chemotherapy or immunotherapy signals ongoing heart damage and triggers closer follow-up.
Protecting the Heart During Treatment
One of the core functions of cardio-oncology is prevention. Two classes of common heart medications, ACE inhibitors (and related drugs called ARBs) and beta-blockers, have been shown to preserve heart pumping function in patients undergoing cardiotoxic cancer treatment. A systematic review of breast cancer patients found that both drug classes provided statistically significant protection during chemotherapy and targeted therapy regimens. The benefit held up whether patients were receiving traditional chemotherapy or newer targeted drugs.
These medications don’t eliminate risk entirely, but they can buy meaningful protection. The goal is to keep the heart strong enough that cancer treatment can continue on schedule. When cardiac function does decline, the 2022 European Society of Cardiology guidelines recommend a graded response: patients with mild or moderate dysfunction can often continue their cancer therapy with increased heart monitoring and the addition of protective medications, rather than stopping treatment altogether. Severe dysfunction, defined as the heart’s pumping capacity falling below 40% or requiring hospitalization for heart failure, calls for more significant treatment changes.
Long-Term Monitoring for Survivors
Cardiac follow-up doesn’t end when cancer treatment does. Current European guidelines recommend that moderate-risk survivors get a heart ultrasound every five years after completing therapy. High-risk and very high-risk survivors need more frequent checks: at one, three, and five years after treatment, with ongoing surveillance beyond that. The specific schedule depends on what treatments a person received, at what doses, and what other cardiovascular risk factors they carry.
This long-term perspective is one of the defining features of cardio-oncology. Traditional cardiology deals with heart disease as it presents. Cardio-oncology anticipates it, sometimes by years, in a population that might otherwise appear healthy. A 35-year-old childhood cancer survivor with no symptoms and a normal-feeling heartbeat may already be developing valve disease or weakening heart muscle that won’t cause problems for another decade. Structured monitoring catches these changes when they’re still manageable.
The Cardio-Oncology Team
Cardio-oncology works best as a multidisciplinary effort rather than a single doctor’s practice. A typical team includes cardiologists with specialized training in cancer-related heart disease, oncologists, radiologists, pharmacists, nurses, rehabilitation specialists, and patient navigators who help coordinate the overlapping demands of cancer and cardiac care. The pharmacist’s role is particularly important because many cardiac and cancer medications interact, and dosing decisions require expertise in both fields simultaneously.
The field has grown rapidly. Dedicated cardio-oncology programs are now established at most major cancer centers, and the European Society of Cardiology published its first comprehensive cardio-oncology guidelines in 2022. For patients, the practical takeaway is straightforward: if you’re being treated for cancer with chemotherapy, targeted therapy, immunotherapy, or chest radiation, cardiac monitoring should be part of your care plan, not an afterthought if symptoms appear.